Krabeva 400 mg contains bevacizumab, a monoclonal antibody used in the treatment of various cancers. It works by targeting and inhibiting the growth of blood vessels that feed tumors. Bevacizumab represents a form of targeted therapy, offering a different approach compared to traditional chemotherapy by interfering with the cancer’s blood supply rather than attacking the cancer cells directly. It is typically used in combination with other chemotherapy drugs and has shown effectiveness in prolonging disease control in several types of cancer.

Mechanism of Action

Bevacizumab works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the formation of new blood vessels. Tumors often release VEGF to ensure they receive an adequate blood supply for growth and survival. By binding to VEGF and preventing it from interacting with its receptors on blood vessel cells, bevacizumab effectively starves the tumor of nutrients and oxygen, slowing its growth and reducing its ability to spread.

Uses

Krabeva is prescribed in the management of several advanced or metastatic cancers, including:

• Colorectal cancer (in combination with chemotherapy)

• Non-small cell lung cancer

• Renal cell carcinoma

• Glioblastoma multiforme (a type of brain cancer)

• Cervical cancer

• Ovarian and fallopian tube cancers

• Hepatocellular carcinoma (in select cases, in combination with immunotherapy)

  Adverse Effects

  Common side effects

  • High blood pressure

  • Fatigue

  • Nosebleeds or minor bleeding

  • Mouth sores

  • Headache

  • Loss of appetite